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Cancer may affect the eye by remote paraneoplastic
effects, indirectly by infiltration or compression of nerves,
and by local or distant metastases. Paraneoplastic
syndromes and symptoms associated with lung cancer
encompass several distinct clinical and pathologic entities.
Cancer-associated retinopathy
The non-metastatic retinopathy related with cancer is
usually referred to as CAR (cancer-associated retinopathy)
[1]. This is a rare syndrome that predominantly occurs
in patients with small cell lung cancer [2-4], although its
occurrence with non-small cell lung cancer [5] has been
described. The other neoplastic diseases may also lead
to CAR [6-9]. The eye autopsy examination of patients
with CAR has revealed patchy losses of photoreceptors of
the extramacular retina and relative sparing of cones;
there may even be complete absence of the retinal
neurones involved in phototransduction [10].
CAR is an autoimmune disorder probably caused
by the remote effects of cancer on the retina or optic
nerve [1]. The autoantibodies that cause CAR specifically
bind to the photoreceptor-specific, calcium binding 23-kD
retinal protein called recoverin [1, 3, 11-15]. This protein
can be found in rods and cones, and – interestingly – also
in small-cell lung cancer cells [16]. However, the serum of
the patients with CAR may contain not only antibodies
against recoverin, but also against other retinal proteins,
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Cancer may affect the eye by remote paraneoplastic effects, indirectly by infiltration or compression of nerves, and by local or
distant metastases. Non-metastatic retinopathy related with lung cancer, called CAR (cancer-associated retinopathy), is an
autoimmune disorder, caused by the remote effects of cancer on the retina and leads to rapidly progressive visual loss. The
autoantibodies that cause CAR bind to a retinal protein called recoverin. The other presentations of paraneoplastic syndromes
involving eyes include encephalomyelitis, Lambert-Eaton syndrome, cerebellar degeneration, and opsoclonus/myoclonus. These
syndromes most frequently occur in association with small-cell lung cancer. Lung cancer may also indirectly involve the eyes
due to infiltration of the cervical sympathetic chain, causing Horner's syndrome due to lung cancer (usually non-small cell
cancer) located in the apex of the lung. The disturbances of the function of cranial nerves may develop because of neoplastic
meningitis or, occasionally, of isolated metastases of cranial nerves in the course of lung cancer. Metastases of the lung
cancer to the eye and orbit occur very rarely and the metastatic tumor to the uvea is the most common form of an intraocular
malignant process.
Oczne objawy raka p∏uca
Rak p∏uca mo˝e wywo∏ywaç oczne objawy zwiàzane z zespo∏ami paranowotworowymi, naciekaniem lub uciskiem nerwów
okoruchowych oraz miejscowymi bàdê odleg∏ymi przerzutami. Paranowotworowym zespo∏em, rozwijajàcym si´ w przebiegu
raka p∏uca, jest autoimmunologiczna retinopatia, nazywana CAR (cancer-associated retinopathy), która szybko prowadzi do
utraty wzroku. Autoprzeciwcia∏a, wywo∏ujàce CAR, wià˝à si´ z bia∏kiem siatkówki, nazywanym rekowerynà. Do innych
zespo∏ów paranowotworowych, wywo∏ujàcych objawy oczne w przebiegu raka p∏uca – najcz´Êciej drobnokomórkowego
nale˝à zapalenie mózgu i rdzenia kr´gowego, zespó∏ Lamberta-Eatona, zwyrodnienie mó˝d˝kowe oraz zespó∏ mioklonii –
opsoklonii. Rak p∏uca (zwykle niedrobnokomórkowy rak szczytu p∏uca) mo˝e wywo∏ywaç zespó∏ Hornera, w nast´pstwie
naciekania szyjnego pnia wspó∏czulnego. Do powstania ocznych objawów w przebiegu raka p∏uca mo˝e prowadziç uszkodzenie
nerwów czaszkowych, spowodowane nowotworowym naciekaniem opon mózgowo-rdzeniowych lub – wyjàtkowo – przerzutami
do nerwów czaszkowych. Bardzo rzadko zdarzajà si´ przerzuty raka p∏uca do oka (zwykle do b∏ony naczyniowej oka) lub do
oczodo∏u.
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e.g. of 34 kD [8], 46 kD [17], 60 kD [4], 65 kd [7] or 70 kD
[14], as well as against enolase [18], or neurofilaments
[14]. Thus, the absence of antibodies aimed at the 23 kD
protein does not exclude the diagnosis of paraneoplastic
retinopathy.
The main symptom of CAR is initially mild and
moderate, and then rapidly progressive, often asymmetric,
bilateral visual loss, which may lead to complete blindness
[4, 9, 18]. Other complaints include photosensitivity, night
blindness, impaired colour vision, light-induced glare,
flashing lights or ring, paracentral, and mid-peripheral
scotomas [3, 9, 18].
Ophthalmologic examination may reveal visual
deterioration, optic disc pallor, narrowing of the retinal
arterioles and clumbing of the retinal pigment epithelium
[4, 9, 11]. The retinal changes are focal and visual field
defects are often heterogeneous [9].
Fluorescein angiography reveals progressive
diminution of peripheral retinal blood flow, slow
perfusion and staining of venules [5]. Electrooculography
shows reduced light peak/dark trough ratio [19].
Electroretinography demonstrates reduced amplitudes
of the cone and rod-mediated responses [7, 11]. Although
the results of ophthalmologic examination are not specific
for CAR, it is postulated to consider the triad of
symptoms: photosensitivity, ring scotomatous visual field
loss and attenuated retinal arteriole calibre highly
suggestive of CAR [11]. The study of visual evoked
responses shows waves either markedly reduced in
amplitude or non-recordable [19]. Demonstration of
antirecoverin antibody in a patient with signs of
retinopathy establishes the diagnosis [15].
CAR is usually observed before the diagnosis of
primary cancer [4, 5, 11]. In rare cases CAR can be
recognised after the primary malignancy was found [3].
Rising antibody titers to the cancer-associated retinopathy
antigen probably occurs before progressive visual field
loss and may be considered an indication for prompt
therapy [2]. More than half of the patients with CAR
have been reported to respond with visual improvement
after systemic steroid therapy [2]. Prednisone treatment
appeared to reduce the patient's antibody titers to normal
[2]. Combined therapy with oral corticosteroids and
plasmapheresis may result in a recovery of vision [4].
Intravenous immunoglobulin may be another treatment
option offered to patients with paraneoplastic visual loss
[18].
Primary tumor treatment (surgical and/or cytotoxic),
optionally combined with corticotherapy (optionally with
plasmapheresis) may cause slight (and/or transitory) visual
improvement in some patients with CAR [4, 5].
Predominantly neurologic paraneoplastic
syndromes with ocular involvement
Paraneoplastic neurologic and ophthalmologic dysfun-
ctions accompanying lung cancer may present as
encephalomyelitis, Lambert-Eaton syndrome, cerebellar
degeneration, and opsoclonus/myoclonus; these para-
neoplastic syndromes most frequently occur in association
with small-cell cancer [20].
The characteristic pathological feature of para-
neoplastic encephalomyelitis is inflammation, perivascular
lymphocytic infiltration, and neuronal loss in diverse
regions of the central nervous system, including the brain
stem, hippocampus, spinal cord and dorsal root ganglia.
The anatomic site of inflammation determines the clinical
presentation (memory loss, behavioural changes, seizures,
weakness, dysarthria, nystagmus, autonomic nervous
system dysfunction). The presence of small cell lung
cancer, predominating neurological symptoms with
normal CT scans, and the presence of anti-Hu antibodies
may help to establish the diagnosis [21].
Paraneoplastic cerebellar degeneration is a clinical
syndrome of subacute, progressive ataxia, which occurs
secondary to degeneration of the Purkinje cells of the
cerebellar cortex. It may be associated with small cell
lung cancer [22]. Clinical features include ataxia, dysartria,
vertigo and ocular manifestations – nystagmus and
diplopia [23]. The cerebrospinal fluid shows mild
pleocytosis, elevated protein and oligoclonal bands. Anti-
Purkinje cell (anti-Yo) antibodies are detected in the
serum or in the cerebrospinal fluid of 50% of patients.
The anti-Yo antibody appears to be specific for paraneo-
plastic cerebellar degeneration associated with gyneco-
logic (breast and ovarian) cancer.
The Lambert-Eaton syndrome afflicts up to 5% of
patients with small cell carcinoma and occurs much less
frequently in patients with non-small cell carcinoma [24].
Neurological symptoms usually precede the diagnosis of
malignancy and usually include proximal lower and/or
upper limb weakness, depressed tendon reflexes and
autonomic dysfunction – especially dryness of the mouth
[25]. The Lambert-Eaton syndrome can also have ocular
manifestations; these include mild/moderate ptosis (in
54% of cases), rarely enhanced ptosis, diplopia, blepharo-
ptosis, blurred vision, abnormal pupil responses to light
and parasympathetic and sympathetic denervation
hypersensitivity of the iris musculature and ophthalmo-
plegia [25-27].
Weakness and autonomic dysfunction in the Lambert
Eaton myasthenic syndrome may be controlled by 3,4-
diaminopyridine; intravenous immunoglobulin or plasma-
pheresis may also provide short-term improvement in
severely affected patients. Prednisolone is indicated in
patients who fail to respond sufficiently to symptomatic
treatment [28]. A combined treatment approach with the
use of chemotherapy and radiotherapy in small-cell lung
cancer, or surgery, radiotherapy and/or chemotherapy
i non-small cell lung cancer together with pharmacological
treatment of neurological symptoms usually results in
a certain improvement [29].
Opsoclonus is a dyskinesia consisting of involuntary,
arrhythmic, chaotic, multidirectional saccades, without
intersaccadic intervals. It is usually associated with
arrhythmic-action myoclonus that predominantly involves
the trunk, limbs and head [30-32]. This syndrome, also
known as the "dancing eyes" and "dancing feet" syndrome,
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is associated with cancer in about 20% of adults, usually
with small cell lung carcinoma and, more rarely, with
non-small cell carcinoma [31]. The onset of this disorder
is subacute and precedes the tumour diagnosis [31].
The opsoclonus/myoclonus paraneoplastic syndrome
is sometimes associated with a specific "anti-Hu" antin-
euronal antibody [30]. This antineuronal nuclear
autoantibody (also known as ANNA-1) is a marker of
neurologic autoimmunity, which is evidently associated
with small-cell lung carcinoma [33]. This antibody stains
the nucleus and cytoplasm of all neurons, and reacts with
a group of 35- to 40-kd proteins in neuronal immunoblots
[34]. The protein targets of ANNA-1 belong to a family of
RNA-binding proteins which probably regulate posttran-
scriptional processing of RNA [34].
Lung cancer indirectly involving eyes
The Pancoast syndrome (or superior pulmonary sulcus
tumor) is associated with bronchogenic carcinoma located
in the apex of the lung; it produces a characteristic clinical
syndrome of neuropathic pain of the upper extremity and
Horner's syndrome. Horner's syndrome is a consequence
of the involvement of the cervical sympathetic chain and
consists of ptosis and the signs of sympathetic ocular
paralysis [35]. A majority of Pancoast tumors are non-
small cell lung carcinoma, but small cell lung carcinoma
and metastatic lesions from a variety of pulmonary and
non-pulmonary malignant tumours may produce an
identical picture [35].
Metastases of lung cancer causing ocular symptoms
Neoplastic neural damage may be caused by extrinsic
compression of a tumour or infiltration of malignant cells
along the nerves of the meningeal layers. Metastases to
the cranial nerves rarely occur as an isolated form; this
process represents in fact a diffuse cancerous menin-
goradiculitis involving the cranial nerves. Neoplastic
processes may affect every cranial nerve. Most patients
had multiple cranial nerve involvement with the fifth and
sixth nerve being the most common site of disease.
Neoplastic meningitis occurs in 10-26% of patients with
lung carcinoma [36]. When cancer cells enter the
subarachnoid space they spread along the leptomeninges,
surround or invade nerve roots, form perivascular cuffs
and enter the Virchow-Robin spaces or penetrate the pia
matter, thus involving the superficial layers of the central
nervous system parenchyma. Diffuse infiltration of the
leptomeninges is a characteristic pattern of tumour
growth. Neoplastic meningitis is pleomorphic in its clinical
presentation. There are neurological disturbances of
cerebral hemispheres (headache, mental status changes,
seizures, ataxia), cranial nerves (double vision, hearing
loss, facial numbness, loss of vision), and spinal cord and
roots symptoms (leg and arm weakness, numbness and
pain).
Lung cancers rarely metastasize to the eye, but
metastatic orbital disease is situated as the third most
frequent malignancy (21%), after breast carcinoma (29%)
and neuroblastoma (25%) [37]. Metastatic tumor of the
uvea is the most common form of an intraocular
malignant process; metastases to the ciliary body, iris,
retina, optic disc, and vitreous are rare [17]. Proptosis
(68%), motility disturbance (57%) and mass (50%) are
the three most common presenting signs of lung
metastases into the eye and orbit [37].
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